Global IVD Growth: Stability, Shifting Markets, and the Road to 2030

The global in vitro diagnostic market continues to expand in both size and strategic importance. According to the 18th edition of Kalorama Information’s The Worldwide Market for In Vitro Diagnostic (IVD) Tests, the industry now represents a $113 billion global market, up from just under $100 billion only five years ago. That growth alone signals resilience, but the geographic distribution of that growth tells an even more compelling story for companies, marketers, and executives shaping long term strategies.

“Globally, in vitro diagnostics is a $113 billion market.”

The United States remains firmly in the lead, accounting for 41% of global IVD sales in 2025. This dominance is well understood across the industry. What may come as more of a surprise is which country holds the second position worldwide and what that reveals about where future opportunities may lie.

A Market Built on Stability and Steady Growth

The IVD market is projected to continue expanding at a mid single digit annual growth rate through 2030, reaching nearly $143 billion. This growth is being driven by ongoing strength in core laboratory testing and a gradual recovery in microbiology. Rather than abrupt disruption, the next phase of the market is expected to be defined by moderate and gradual shifts across product categories.

These shifts are largely rooted in long term demographic and epidemiological forces. Aging populations, rising disease burdens, and expanding healthcare infrastructure are providing strong underlying support for diagnostics demand worldwide. At the same time, fiscal realities are shaping purchasing behavior. Tighter government funding in the United States, budget constraints across the European Union, and limited hospital spending in China are all factors that will temper growth, even as overall demand remains strong.

Global Growth Is Uneven but Essential

While the United States leads the market, IVD diagnostics are growing in every region of the world. Some markets are expanding faster than others, often influenced by social, political, and economic conditions unique to each country. Despite these variations, diagnostics continue to play a central role in the evolution of global healthcare systems.

“While the United States leads the market, IVD diagnostics are growing in every region of the world.”

International revenue has long been a cornerstone of the IVD industry. Every major diagnostics company generates sales in the United States, the European Union, and the Asia Pacific region at a minimum. However, operating globally has become more complex. Many emerging countries have already selected preferred vendors and implemented policies designed to control healthcare spending growth. In recent years, geopolitical pressures such as tariffs and trade policies have added further uncertainty, with the potential to disrupt supply chains and impact vendors worldwide.

Beyond North America, a Diverse Set of Key Markets

Outside of North America, where Canada joins the United States as a top ten IVD market, a diverse group of countries stands out as strategically important. Australia, Brazil, China, France, India, Italy, Japan, Spain, Turkey, and the United Kingdom all represent significant opportunities for IVD companies with global ambitions.

Among these markets, one country deserves particular attention. Germany is not only one of the top ten fastest growing IVD markets, but it is also the second largest IVD market globally, trailing only the United States. This positioning challenges common assumptions that the next largest opportunities must be found in emerging economies alone.

“Germany is both a top‑ten growth market and the world’s second‑largest IVD market.”

Germany’s Quiet Strength

Germany’s IVD market is widely regarded as mature, yet it continues to demonstrate solid growth and is expected to do so through 2030. This performance underscores an important point for industry leaders. Market maturity does not necessarily imply stagnation.

Future growth in Germany is expected to be driven by innovative diagnostic technologies, particularly in areas such as histology, fecal occult blood diagnostics, glucose monitoring, and point of care solutions that support healthcare delivery in rural settings. These segments reflect both technological advancement and practical healthcare needs, making Germany a compelling example of how established markets can continue to evolve.

For companies and marketers, Germany illustrates the value of aligning innovation with clinical demand and healthcare system priorities rather than focusing solely on geographic expansion into less developed markets.

Kalorama explores regional trends like this more in 30-Country IVD Market Atlas, 2025.

Emerging Markets and Expanding Access

Looking ahead to 2030, increased access to healthcare insurance in countries such as Brazil, India, China, Mexico, and Saudi Arabia is expected to create larger than anticipated short term opportunities. As coverage expands, new patient populations will enter the healthcare system, driving demand for diagnostic testing across a range of settings.

China continues to attract significant attention, and rightly so, but it is far from the only growth story in Asia. Markets such as Indonesia, South Korea, and Vietnam are emerging as natural targets for large IVD companies seeking diversification and long term expansion. Similarly, additional opportunities are developing across Latin America beyond Brazil, as well as in the Middle East and Eastern Europe.

What This Means for Industry Leaders

For executives and decision makers, the evolving global IVD landscape reinforces the need for balanced strategies. The United States will remain the cornerstone of global revenue, but growth outside the US is not optional for companies looking to sustain momentum. Germany’s position as the world’s second largest IVD market serves as a reminder that opportunity can come from stability as much as from rapid expansion.

The next decade will reward organizations that understand not just where the biggest markets are today, but how healthcare access, innovation, and policy are shaping demand tomorrow. In a $113 billion market that continues to grow, the question is no longer whether global expansion matters, but where and how to pursue it most effectively.